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BACKGROUND: Redox and proteotoxic stress contributes to age-dependent accumulation of dysfunctional mitochondria and protein aggregates, 
and is associated with neurodegeneration. The free radical 
theory of aging inspired many studies using reactive 
species scavengers such as alpha-tocopherol, ascorbate and 
coenzyme-Q to suppress the initiation of oxidative stress. 
However, clinical trials have had limited success in the 
treatment of neurodegenerative diseases (NDDs).
CONTENT: The misfolding and aggregation of specific 
proteins is a seminal occurrence in a remarkable variety 
of NDDs. In Alzheimer’s disease, the two principal 
aggregating proteins are β-amyloid (Aβ) and tau. The 
abnormal assemblies formed by conformational variants 
of these proteins range in size from small oligomers to the 
characteristic lesions that are visible by optical microscopy, 
such as senile plaques and neurofibrillary tangles. 
Pathologic similarities with prion disease suggest that the 
formation and spread of these proteinaceous lesions might 
involve a common molecular mechanism, corruptive protein 
templating. The accumulation of redox modified proteins 
or organelles cannot be reversed by oxidant intercepting 
antioxidants and must then be removed by alternative 
mechanisms. Autophagy serves this essential function in 
removing damaged or dysfunctional proteins and organelles 
thus preserving neuronal function and survival.
SUMMARY: Senescent cells and their senescence-
associated secretory phenotypes (SASPs) may constitute a 
novel, understudied, and potentially important contributor 
to neuro-inflammation and subsequent neurodegeneration. 
Characterization of cellular senescence in the brain could 
uncover novel therapeutic targets for the prevention and 
treatment of chronic age-related NDDs.
KEYwORDS: brain, aging, neurodegeneration, DNA 
damage, senescence, neuro-inflammation, mitochondria, 
lysosome, proteostasis, prion, amyloidosis
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Abstract
Introduction
Neurodegenerative disorders are becoming increasingly 
prevalent worldwide, and are a growing burden on the aging 
population.(1)  According to a 2015 United Nations report 
on world population aging, the number of people aged 60 
and older worldwide is projected to more than double in 
the next 35 years, reaching almost 2.1 billion people.(2,3) 
Aging is a natural process characterized by a progressive 
functional decline of tissues, organs, and organ systems, 
which leads to an increased susceptibility to age-related 
diseases and, ultimately, to death. A persistently DNA 
damage response (DDR), known as “cellular senescence”, 
is one of the main contributing factor to age-associated 
tissue dysfunction, reduced regenerative capacity, and age-
related diseases.(4-6).
 Neurodegenerative diseases (NDDs) such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), 
amyotrophic lateral sclerosis (ALS), and frontotemporal 
lobar dementia are among the most pressing problems 
of developed societies with aging populations. Neurons 
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carry out essential functions such as signal transmission 
and network integration in the central nervous system and 
are the main targets of NDD.(7) Neurodegeneration by 
definition disturbs the properties of the Central Nervous 
System (CNS) and therefore affects neuronal function, 
as well as the structure or survival of neurons.(7) The 
development of therapies aimed at mitigating or delaying 
age-related NDDs is a major priority for the biomedical 
community due to the enormous social, emotional and 
economic burden associated with them. The disappointing 
outcomes of dozens of phase III clinical trials of treatments 
for AD and PD indicate a need for fresh approaches to 
identify novel targets that drive processes that cause age-
related neuropathology.(8) Currently available treatments 
(social supports, mobility aides, and “Band-Aid” treatments 
for end-stage, downstream symptoms) are not directed at 
the root causes of age-related dysfunction. Treating chronic 
diseases one at a time does not suffice.(9)
 Clearly, clinical practice would be transformed if 
mechanism-based treatments could be devised that break 
the link between fundamental aging processes and chronic 
diseases, making aging a modifiable risk factor. The recent 
awareness that age-related disorders can be driven by 
one or more basic aging processes has inspired efforts to 
identify these processes and develop strategies, preferably 
pharmacological in nature, to intervene.(10) Rapid advances 
in molecular genetics and neuroimaging will improve our 
understanding of the pathogenetic mechanism underlying 
the earliest stages of the detrimental processes increasing 
the vulnerability for neurodegeneration later in life.(11,12) 
Prevention of NDDs of the elderly might begin during the 
fetal and childhood life by providing the mothers and their 
children a healthy environment for the fetal and childhood 
development. This might also help to cope better with the 
life-long  environmental  influences  and  with  genetic 
factors.
Aging and NDD
Population-based autopsy studies of the brains of aged 
people who had not been diagnosed with a neurological 
disease consistently report the presence of amyloid plaques, 
neurofibrillary tangles, Lewy bodies, inclusions of TAR 
DNA-binding protein 43 (TDP-43), synaptic dystrophy, the 
loss of neurons and the loss of brain volume in most of the 
brains.(12) These features vary greatly between individuals, 
with particular lesions dominating a particular brain or 
restricted to specific regions.(3)
 The presence of age-related protein abnormalities 
and inclusion bodies in the aging brain points to defects in 
proteostasis, an idea that is supported by mounting evidence 
from experiments. According to one such hypothesis, in 
normal aging, macromolecules become oxidized and can no 
longer be degraded by lysosomes. This leads to the further 
production of lysosomal enzymes that are also unable 
to digest the cellular material. A well-known deposit that 
results from lysosomal inefficiency is lipofuscin, which 
is an accepted marker of aging for postmitotic cells.(13) 
Similarly, the increase in damaged proteins and dying 
cells that accompanies aging can overwhelm phagocytic 
processes and lead to an accumulation of material in 
lysosomes. Indeed, myelin debris have been demonstrated 
to accumulate in aging microglia, in which it forms 
insoluble, lipofuscin-like lysosomal inclusions.(14) With 
aging, and even more so with neurodegeneration, the brain 
shows increased levels of many lysosomal proteins and 
enzymes, and neurons and other cell types show abnormal 
endosomes, lysosomes and autophagosomes.(15-17)
 The aggregation of misfolded proteins is a 
characteristic feature of aging as well as aging-related 
NDDs.(18,19) The most common altered proteins observed 
in aging brains are hyperphosphorylated-t (HPt) and 
b-amyloid (Ab) (i.e., hallmark lesions of AD), a-synuclein 
(SymbolS) (i.e., hallmark lesions of PD/dementia with 
Lewy bodies (DLB)), and transactive response TDP43 
(i.e., hallmark lesions of frontotemporal lobar degeneration 
with TDP (FTLD-TDP), and amyotrophic lateral sclerosis 
(ALS)).(20-26) Each of these protein alterations seem to 
progress neuro-anatomically in an orderly manner from a 
presumed initiation/predilection site. When the most severe 
stages of the progression are reached, these altered proteins 
were considered to be causative of NDDs such as AD, PD, 
DLB, FTLD-TDP and ALS.(27-33)
 Recently, a new entity, primary age-related tauopathy 
(PART), which describes neurologically unimpaired aged 
subjects with HPt pathology in the hippocampus, has been 
defined.(34) It has even been debated whether subjects 
with PART represent an early stage of AD or merely reflect 
a neurodegenerative process at an early stage.(35) Also, 
“acute or incidental” aS pathology has been reported to 
be seen in 5% to 31% of the cognitively unimpaired aged 
subjects (36,37), and Ab has been reported in the cortex 
of 39% to 82% of cognitively unimpaired aged subjects 
(38,39). TDP43 pathology has been reported in 3% to 
40% of cognitively unimpaired aged subjects.(40,41) The 
later is frequently associated with hippocampal sclerosis.
(42) Experimental evidence suggests a complex scenario, 
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DNA Damage and NDD
Biological tissues require oxygen to meet their energetic 
demands. However, the consumption of oxygen also results 
in the generation of free radicals that may have damaging 
effects on cells. The brain is particularly vulnerable to the 
effects of reactive oxygen species (ROS) due to its high 
demand for oxygen, and its abundance of highly peroxidisable 
substrates. Oxidative stress is caused by an imbalance in the 
redox state of the cell, either by overproduction of ROS, or by 
dysfunction of the antioxidant systems.(47) ROS contribute 
to the development of neurodegeneration by modulating 
the function of biomolecules. ROS may target several 
different substrates in the cell, causing protein, DNA, RNA 
oxidation, or lipid peroxidation The oxidation products of 
Figure 1. Cell-specific and pathway-specific 
acceleration of aging.(3) (Adapted with permission 
from Springer).
including mitochondrial dysfunction, compromised 
stress responses, synaptic rearrangements and altered 
protein expression, to cause age-related brain changes. 
neurodegenerations were traditionally defined as disorders 
with selective loss of neurons and distinct involvement of 
functional systems defining clinical presentation.
 Classification of neurodegenerations is based on 
clinical presentation, anatomical regions and cell types 
affected, conformationally altered proteins involved in 
the pathogenetic process, and etiology if known, e.g., 
genetic aberrations. Currently, ‘‘the-winner-takes-it-all’’ 
approach supports classification of diseases according to the 
predominant protein that is deposited in the brain.(43) The 
basis of this classification is to evaluate where the deposits 
composed of particular proteins are found. Extracellular 
deposits comprise deposits with immunoreactivity for 
Ab or prion protein (PrP), while proteins that deposit 
intracellularly include t, aS, TDP-43, or so called FET 
proteins (FUS: fused in sarcoma, EWS: ewing sarcoma 
protein, TAF15: TATA-binding protein-associated factor 
15).(43,44) These proteins associate with sporadic and 
inherited forms, while there are further proteins, which are 
related to genetic diseases, like those linked to trinucleotide 
repeat disorders. These proteins deposit in various cell 
types (neuron, astro- and oligodendroglia). Indeed, some 
neurodegenerations show predominantly oligodendroglial 
protein deposits (like the a-synucleinopathy multiple system 
atrophy, or tauopathies with globular glial inclusions) 
(45,46), which raise the issue that non-neural cells are also 
important components of neurodegenerations pathology. 
Thus, evaluating proteins and pathways that are important 
in age-related neurodegeneration in the developing brain 
together with the characterization of mechanisms important 
during brain development with relevance to brain aging are 
of crucial importance.
 Elucidation of complex pathogenetic routes 
characterizing the earliest stage of the detrimental processes 
that result in pathological aging represents an essential 
first step toward a therapeutic intervention which is able 
to reverse these pathological processes and prevent the 
onset of the disease.(11) Given that, NDDs in the elderly 
are common. Disease-free brains, especially in the oldest-
old, are rare. It is possible that normal brain aging forms 
a continuum with neurodegeneration and disease, and 
that stochastic factors, framed by a person's genetics and 
environment, determine the type of NDD that will dominate 
their brain eventually (Figure 1).
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polyunsaturated fatty acids, especially arachidonic acid 
and docosahexanoic acid which are abundant in brain, 
are malondialdehyde and 4-hydroxynonenal. ROS attacks 
protein, oxidizing both the backbone and the side chain, 
which in turn reacts with amino acid side chains to form 
carbonyl functions. ROS attacks nucleic acids in a number 
of ways, causing DNA-protein crosslinks, breaks in the 
strand, and modifies purine and pyridine bases resulting in 
DNA mutations.(47)
 Damage to a cell’s genomic DNA is particularly 
harmful because DNA is the blueprint for protein production 
and, unlike other molecules, it cannot simply be replaced 
by resynthesis. DNA damage induces mutations and 
chromosomal aberrations that can lead either to cellular 
dysfunction or to the formation of cancer, and encounters 
with certain DNA lesions can derail transcription and 
replication, and thereby trigger cell death, senescence, and 
aging (48). Accordingly, cells devote enormous resources 
for the purpose of genome maintenance and have evolved 
elaborate systems to repair damaged DNA.(49) The 
consequences of genomic instability manifest in at least 
three important ways with age (Figure 2). The first is an 
accumulation of unrepaired DNA damage, which can arise 
from a decrease in DNA repair activities with age. For 
instance, a decline in the efficiency of base excision repair 
(BER) and non-homologous end joining (NHEJ) due to a 
reduction in the activity of DNA glycosylases and DNA-
dependent protein kinase (DNA-PK), respectively, has been 
reported in the literature. An age-dependent attenuation in 
DNA repair capacity has also been reported in the rodent 
and human brain.
 Another way in which DNA damage participates in 
aging is through the erroneous repair of DNA lesions that 
results in mutations.(50) In contrast to unrepaired lesions, 
which are reversible, mutations are irreversible and can 
therefore be highly problematic. In addition to direct 
alterations to the composition and structure of DNA, the 
formation of DNA damage also elicits substantial changes 
to chromatin organization.
 Thus, DNA damage could progressively alter 
chromatin conformation, and thereby, gene expression 
patterns, with age. In fact, a number of studies have 
reported age-associated changes in the epigenome (50-52), 
although precisely what fraction of these changes is a result 
of DNA damage remains unclear. In addition to normal 
aging, defective DNA repair has also been linked with age-
associated neurodegenerative disorders such as AD, PD and 
ALS. For instance, elevated levels of DNA strand breaks, a 
reduction in the levels of double strand break (DSB) repair 
proteins such as DNA-PKcs and MRE11–RAD50–NBS1 
(MRN) complex proteins, and decreased BER activity have 
been described in AD patients compared to age-matched 
controls (53-56). Similarly, elevated levels of oxidative 
lesions and single strand breaks (SSBs) have been reported 
Figure 2. The Consequences of DNA Damage 
in Aging and Neurodegeneration.(49) (Adapted 
with permission from Cell Press).
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Figure 3. Errors in an error-correcting mechanism.(1) (Adapted 
with permission from Springer).
in the neurons of ALS patients and damage to mitochondrial 
DNA has been documented in PD.(57-59) While these 
studies certainly raise the possibility that defects in the DDR 
underlie brain aging and the development of age-related 
neurodegenerative disorders,
 It is becoming increasingly clear that the DNA damage 
response is important during both neural development and 
in the mature nervous system. Mutations in core DNA repair 
factors are either incompatible with life, or, even when 
tolerated, manifest in severe neurodevelopmental disorders. 
On the other hand, determining the specific contribution of 
DNA damage to brain aging and neurodegeneration remains 
a complex problem. The vulnerability of postmitotic neurons 
to certain types of DNA damage (such as oxidative lesions 
or certain DNA strand break lesions) coupled with a gradual 
decline in the activities of corresponding repair mechanisms 
could lead to their accumulation with age and contribute to 
brain aging and neurodegeneration.(49) Identification of a 
previously uncharacterized genetic disease highlights DNA 
repair as a shared mechanism in neurodegenerative disorders, 
and suggests potential therapeutic approaches to tackling 
them. An error in error-correcting might also happens (Figure 
3).(1) DNA-repair enzymes also modify the age of onset of 
several other NDDs caused by polyglutamine expansion. In 
addition, DNA-repair mechanisms have been implicated in 
the pathogenesis of such polyglutamine diseases. Perhaps 
clustering of mutant polyglutamine-expanded proteins near 
DNA inhibits the recruitment and release of repair enzymes, 
interfering with cellular DNA repair. Relationships between 
the pathways involved in DNA repair and in polyglutamine- 
expansion diseases are becoming apparent.(1,60)
 How do DNA-repair defects bring about 
neurodegeneration? One possibility is that, over time, 
aberrant DNA repair results in a progressive accumulation 
of oxidative damage to DNA. This damage causes 
broad changes, both in DNA sequence and in epigenetic 
modifications, which alter gene expression without changing 
the underlying DNA. Over time, these changes could 
cause a loss of normal neuronal functi and DNA-damage 
levels would cross a threshold, leading factors involved in 
maintaining genomic integrity, such as the protein p53, to 
trigger programmed cell death and neuronal loss.
 In the future, poly ADP ribose polymerase (PARP), 
ataxia-telangiectasia mutated (ATM), p53 and other repair-
related proteins could prove to be therapeutic targets 
for NDD. Hopes for treating these diseases 25 years ago 
focused on DNA and genetic studies.w We may now have 
come full circle, back to DNA. Time, and further studies, 
will be needed to elucidate these mechanisms in more detail, 
and to determine whether such treatments could be useful in 
NDDs.(1)
Cellular Senescence and The SASP in NDD
The cell cycle consists of elaborate feedback mechanisms 
and regulatory checkpoints that are typically divided into 
four phases: S-phase, during which DNA replication occurs, 
M-phase, where cell division, or mitosis, takes place, and the 
gap phases that separate the two; G1 and G2, respectively. 
Additionally, quiescent cells, such as many of the neurones 
in the adult hippocampus, exist in a non-dividing, silent 
phase known as G0. Once in this phase, cells are deemed 
terminally differentiated, meaning they are not capable of 
re-entering the cell cycle.(61,62) It is in this capacity that 
vulnerable neurones are affected. As increasing evidence 
indicates, cells that exist in G0, and thus are no longer 
mitotically active, become wrongly reactivated in AD and 
other NDDs, and are forced through a cell cycle that they 
are no longer capable of completing.(63-66)
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 Senescence is a process of mitotic arrest of the cell 
cycle, which is started in the G1/S check-point.(67) During 
this state the cell experiences several modifications, such 
as changes in morphology, metabolism and expression of 
cytokines and growing factors. These changes result in 
what is known as the SASP.(68) It has been considered 
that senescence might be caused by a series of biological 
processes, including telomere shortening, oxidative stress, 
DNA damage, calcium dysregulation, misfolded proteins 
and oncogene expression.(69) Senescence is divided 
into replicative senescence, stress-induced premature 
senescence (SIPS) and oncogene-induced senescence, 
being SIPS the most important for the CNS.(70) Premature 
senescence caused by stress can involve telomere-dependent 
or telomere-independent mechanisms.(67) Mitochondria 
play an important role in senescence, as they are among 
the organelles that produce more oxidative stress and their 
dysfunction has been associated with high levels of ROS in 
senescent cells (71) and during aging (72).
 Cellular senescence has been described more than 
50 years  ago  as  a  process  that  limits  the  growth  of 
normal human cells in culture. Cellular senescence is 
closely interconnected with aging, longevity, and age 
related diseases by sharing common genes, regulators, and 
multiple signaling pathways.(73) Senescence is associated 
with cellular mechanisms that trigger NDDs and other 
aging-associated process. It has been shown that senescence 
involves mitochondrial dysfunction, morphological 
changes, activation of p38 mitogen-activated protein 
kinases (p38MAPK) and increased secretion of proteins and 
factors, such as a-galactosidase and interleukin (IL)-6, by 
astrocytes and neurons (74,75), in both normal aging and 
neurodegenerative conditions, such as AD and PD. Another 
important factor for senescence is telomere length, although 
its role in neurological diseases is still controversial. Several 
studies have found that telomere loss is associated with 
diseases such as schizophrenia (76), depression (77) and AD 
(78). A recent meta-analysis of 13 primary studies (including 
860 AD patients and 2022 controls) found shorter telomeres 
in AD patients.(79)
 In addition to arresting growth, senescent cells 
express a SASP, the robust secretion of many inflammatory 
cytokines, growth factors and proteases.(80,81) SASP 
factors include several ILs, monocyte chemotactic 
proteins (MCPs), growth-related oncogenes (GROs), and 
inflammatory cytokines as granulocyte–macrophage colony 
stimulating factor (GM-CSF) and macrophage inflammatory 
proteins (MIPs), among others.(80,82,83) SASP factors can 
have potent effects on neighboring cells and thus can alter 
local and systemic tissue milieus. In the brain, it seems that 
the increase in p16INK4a expression is linked to the decline in 
the number of progenitor cells and consequently to reduced 
neurogenesis.(84) Moreover, studies on animal models of 
accelerated aging have indicated that the premature aging 
is associated with an increased level of senescence markers 
in their tissues.(85) The aging brain displays several typical 
stress response indicators: (i) increased oxidative stress with 
damage in nuclear DNA (86) and in cellular proteins (87), (ii) 
protein misfolding and aggregation (88), (iii) disturbances 
in calcium homeostasis (89), (iv) mitochondrial dysfunction 
and energy deficiency (90) and (v) accumulation of 
pigmented autophagic vacuoles containing lipofuscin, 
neuromelanin and ceroid (91). Many of these changes are 
typical changes associated with cellular senescence and 
the SASP. Several gene expression profiling studies in 
brain have revealed that aging is linked to the increase in 
the expression of stress response and inflammatory genes 
and a decrease in gene expression associated with synaptic 
transmission, calcium homeostasis and mitochondrial 
function (92-94).
 The brain is basically composed of two different kinds 
of cells: glial cells (astrocytes and microglia) and neurons. 
Astrocytes are involved in the modulation of synaptic 
neuronal function and plasticity (95), while microglia 
work as resident macrophages (96,97), providing immune 
surveillance and mediating innate immune responses to 
pathogens or injuries. Neurons are terminally-differentiated 
post-mitotic cells while glia, particularly microglia, are the 
only adult cell type in the CNS that exhibit a significant 
mitotic potential, and are susceptible to telomere shortening. 
Increasing evidences are showing that senescent cells 
are detectable in mammalian brains along with the aging 
process, and may also be implicated in NDDs.(8,98,99) As 
an indicator of cellular senescence telomere length has been 
proposed as a biomarker of human aging.(100) In general, 
telomere length reflects the balance between additions and 
losses of TTAGGG repeats (101) and it can be accelerated 
by many factors, such as oxidative stress, replication stress, 
and inflammation (102). Epidemiologists have measured 
telomere length in cohort studies and suggested that 
measurement of telomere length in white blood cells can 
be used as a surrogate marker of telomere length in other 
tissues/organs (103). Overall these observations suggest that 
telomere stability and maintenance are required for brain 
functions. Advanced age and presence of intra-cerebral 
A deposit are known to contribute to the development of 
neurodegenerative alterations in AD. Microglial cells exhibit 
significant telomere shortening and reduction in telomerase 
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activity in normally aging rats as well as a faster telomere 
shortening rate in human microglia along with dementia 
progression.(104) The authors suggested that telomere 
shortening contributes to degeneration of microglia as a 
contributing factor in the pathogenesis of AD.(6) 
 Strategies directed to counteract the molecular changes 
in senescent cells have been explored. Several studies have 
found that telomerase has neuroprotective effects in the 
brain and it has been shown that its expression and activity 
are increased after injury. Telomerase is a ribonucleoprotein 
responsible for telomere length maintenance, and it has 
been demonstrated that its protein component (telomerase 
reverse transcriptase (TERT)) has extra-telomeric functions, 
which are important for post-mitotic cells such as neurons.
(105) TERT overexpression is associated with decreased 
ROS levels (105) and with the reduction of excitotoxicity 
induced by N-methyl-D-aspartate (NMDA) in neurons 
(106). TERT has effects on neuronal survival because it 
regulates Bcl2/Bax expression.(107) Therefore, TERT 
could be considered as a key protective protein since it may 
Figure 4. Overview of possible neuroprotective mechanisms of TERT in cells from the CNS and possible strategies to increase 
TERT expression and telomerase activity.(108) (Adapted with permission from Esevier B.V). BDNF: brain-derived neurotrophic 
factor; MAPK: mitogen-activated protein kinases; CREB: cAMP responsive element binding; TRF: telomeric repeat factor; Bcl2: B-cell 
lymphoma 2; Bax: Bcl-2-associated X; PI3K: phosphoinositide 3-kinase.
decrease some secretory phenotypes of senescence in the 
brain, which have been associated with the onset of NDDs 
(Figure 4).(79,108)
 Upon stress signaling events, such as those triggered 
by the exposition to a high dose of exogenous H2O2, TERT 
is translocated from the nucleus to the cytoplasm and this 
process is regulated by Src kinase family inhibitor protein 
phosphatase 1 (PP1), since TERT is phosphorylated in 
a tyrosine at position 707.(109) In the nucleus, TERT 
is regulated by protein tyrosine phosphatase 2 (Shp-2).
(110) TERT is imported from the cytoplasm to the nucleus 
through Akt-mediated phosphorylation at serine 227 and 
its interaction with heath shock protein 90 (Hsp90). TERT 
localization is also regulated by interaction with other 
proteins such as nuclear factor kappa B (NF-kB) and tumor 
necrosis factor a (TNF-a) (111). TERT has a mitochondrial 
targeting signal and, therefore, TERT can enter the 
mitochondrial matrix where it interacts with mitochondrial 
DNA and mitochondrial tRNA (112). Several studies have 
evidenced that TERT is translocated from the nucleus to the 
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mitochondria in response to oxidative stress.(109,113,114) 
Recently, TERT has been postulated as a therapeutic target 
for NDDs due to its protective role in oxidative stress and 
DNA damage after injury, especially in injured spinal cord 
(115), neonatal hypoxic-ischemic brain injury (116) and 
in an amyotrophic lateral sclerosis animal model (117). 
However, few studies have analyzed TERT expression and 
telomerase activity in the human CNS.(108)
Neuro-inflammation in NDD
Aging is a ubiquitous complex phenomenon that results from 
environmental, stochastic, genetic, and epigenetic events 
in different cell types and tissues and their interactions 
throughout life. A pervasive feature of aging tissues and 
most if not all age-related diseases is chronic inflammation. 
“Inflammaging” describes the low-grade, chronic, systemic 
inflammation in aging, in the absence of overt infection 
(“sterile” inflammation), and is a highly significant risk factor 
for both morbidity and mortality in the elderly people.(118) 
Inflammaging most likely derives from, but is not limited to, 
the sources described here. These sources are not mutually 
exclusive, and their relative contributions require further 
studies. One source of inflammaging could be the damaged 
macromolecules and cells (self-debris) that accumulate 
with age due to increased production and/or inadequate 
elimination. Self-debris released as a consequence of cell/ 
organelle injury can mimic bacterial products and function 
as endogenous “damage”-associated molecular patterns that 
activate innate immunity.(119)
 A second source of inflammaging might be represented 
by harmful products produced by the microbial constituents 
of the human body, such as oral or gut microbiota, which 
can leak into surrounding tissues and the circulation.(120) 
Presumably, the ability of the gut to sequester these microbes 
and/or their products declines with age, leading to chronic 
low-grade inflammation. Alternatively, the gut microbiota 
itself might change with age so that the microbes present in 
the aged, but not young, gut elicit an inflammatory response.
(119)
 Mitochondria play a major role in inflammaging and 
in the activation of NLR family pyrin domain containing 
3 (Nlrp3) inflammasome. The Nlrp3 inflammasome is a 
multiprotein complex that can activate pro-caspase-1 in 
response to cellular danger resulting in the processing and 
secretion of the proinflammatory cytokines IL-1β and IL-
18. Most activators of the Nlrp3 inflammasome induce the 
generation of mitochondrial ROS. Third, inflammaging 
might be due to cellular senescence. Senescence is a cellular 
response to damage and stress. Mechanistically, senescent 
cells likely fuel age-related disease because they secrete 
numerous proinflammatory cytokines that modify the tissue 
microenvironment and alter the function of nearby normal 
or transformed cells.(121,122) Senescent cells accumulate 
with age in many tissues and are prominent at sites of many 
age-related pathologies.
 Emerging evidence suggests that inflammation has a 
causal role in disease pathogenesis, and understanding and 
control of interactions between the immune system and the 
nervous system might be key to the prevention or delay of 
most late-onset CNS diseases. In AD, neuro-inflammation 
is not a passive system activated by emerging senile 
plaques and neurofibrillar tangles, but instead contributes as 
much (or more) to pathogenesis as do plaques and tangles 
themselves.(123) The important role of neuro-inflammation 
is supported by findings that genes for immune receptors, 
including triggering receptor expressed on myeloid cells 
2 (TREM2) (124) and cluster of differentiation (CD)33 
(125,126), are associated with AD (127).
 Detection of pathological triggers is mediated by 
receptors that recognize danger-associated molecular 
patterns (DAMPs) or pathogen-associated molecular patterns 
(PAMPs). In AD, microglia are able to bind to soluble Aβ 
oligomers and Aβ fibrils via cell-surface receptors, including 
SCARA1, CD36, CD14, α6β1 integrin, CD47, and toll-like 
receptors (TLRs) such as TLR2, TLR4, TLR6, and TLR9 
(128-131), and this process is thought to be part of the 
inflammatory reaction in AD. Binding of Aβ with CD36, 
TLR4, and TLR6 results in activation of microglia, which 
start to produce proinflammatory cytokines and chemokines. 
In turn, genetic deletion of CD36, TLR4, or TLR6 in vitro 
reduces Aβ- induced cytokine production (130,132,133) and 
prevents intracellular amyloid accumulation and activation 
of multiprotein complexes known as inflammasomes (133).
 Neuroinflammation has been famously difficult to 
define in relation to NDD. In contrast, neuroinflammation 
in multiple sclerosis (MS) is unambiguous, comprising 
often florid infiltration of the CNS parenchyma by blood-
derived lymphocytes and monocyte-derived macrophages, 
accompanied by frank impairment of blood-brain barrier 
(BBB) function and intense glial reaction. Neuro-
inflammation in diseases such as AD, PD, and ALS is 
typified instead by a reactive morphology of glial cells, 
including both astrocytes and microglia, accompanied by 
low to moderate levels of inflammatory mediators in the 
parenchyma. This reaction, both cellular and molecular, is 
not distinguishable between one disease and another or from 
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other conditions such as stroke or traumatic injury. Given 
this lack of specificity, it is easy to conclude that the glial 
reaction is secondary to neuronal death or dysfunction and is 
accordingly unlikely to provide useful targets for therapeutic 
intervention or topics for intensive investigation.(7)
 Given this difficulty of using reductionist experimental 
approaches to evaluate glial neuroinflammatory properties, 
and in view of the nonspecific nature of cardinal inflammatory 
changes in glia during NDD, it seems reasonable to 
propose an all-purpose definition of neuroinflammation in 
neurodegeneration: contributions by glial cells, elements 
of the BBB, or systemic inflammatory processes that 
are harmful or beneficial to the severity of NDD. This 
broad definition acknowledges the primacy of neurons in 
brain function and disease and further recognizes that the 
glial reaction to neuronal injury, dysfunction, or death 
may be helpful or harmful (or neutral).(7) In addition, as 
inflammation in AD primarily concerns the innate immune 
system, unlike in ‘typical’ neuroinflammatory diseases such 
as multiple sclerosis and encephalitides, the concept of 
neuro-inflammation in AD may need refinement.(134)
Mitochondrial – Lysosomal Dysfunction in NDD
Neurons have an exceptionally high demand for ATP, which 
is needed for axonal transport, maintenance of ion gradients 
and membrane potential, and generation of synaptic 
vesicles. ATP production in neurons relies predominately 
on oxidative phosphorylation. Therefore, mitochondrial 
health is essential for neuronal function.(135) Given these 
unique features of neurons, the nervous system may be 
especially sensitive to mitochondrial damage. Dysfunctional 
mitophagy is closely linked to PD, a neurodegenerative 
disorder characterized by a loss of dopaminergic neurons 
in the substantia nigra as well as the accumulation of Lewy 
bodies, a form of protein aggregates.(136)
 Aging is associated with a loss of physiological 
integrity, including an imbalance in proteostasis and an 
increase in mitochondrial dysfunction, which can be caused 
by compromised autophagy and its subtype mitochondrial 
autophagy, termed mitophagy. Autophagy is the process 
by which cellular components are degraded and recycled 
within the cell. Autophagy can refer to the nonspecific, 
cell-wide degradation of organelles or misfolded proteins 
in nutrient-starved conditions, as well as the removal of 
specific damaged or superfluous organelles. Aging and 
age-related pathologies are associated with reductions in 
autophagy (137), and emerging evidence suggests that 
the upregulation of autophagy may delay the onset and 
ameliorate the symptoms of age-related phenotypes (138). A 
reduction in autophagy leads to neurodegeneration in mice 
(139-141) and is thought to contribute to several NDDs in 
humans (17). Mitochondria, classically referred to as the 
“powerhouse” of the cell, produce cellular energy in the 
form of ATP. However, a large body of work has established 
additional and synergistic roles of the mitochondria in the 
regulation of cellular homeostasis.(142) Mitochondrial 
dysfunction is considered a hallmark of aging (143), and 
is implicated in apoptosis, senescence, genome instability, 
inflammation, and metabolic disorders (142,144). The term 
“mitophagy” was first coined by Dr. Lemasters in 2005.
(145) Since then, mitophagy has been linked to various 
diseases, including neurodegenerative disorders (146) such 
as PD (147), Huntington's (148), and AD (149), as well as 
normal physiological aging (150).
 Determining what controls mitochondrial fitness is 
important for a better understanding of neurodegeneration 
and arming us with the knowledge that may help design 
better therapeutic strategies. How cellular bioenergetics, 
oxidative stress and autophagic-lysosomal activities are 
cross regulated is also important. It is clear that mitochondrial 
activity and oxidative stress are intertwined as mitochondria 
are sensitive to ROS damage while simultaneously 
generating ROS for cell signaling. Indeed, inhibiting 
the mitochondria’s antioxidant defense mechanisms is 
deleterious to not only the mitochondria, but the cell as a 
whole, as best evidenced by superoxide dismutase 2 (SOD2) 
deletions or mutations.(151) Furthermore, inhibition of the 
mitochondrial glutathione transporter increases neuron 
sensitivity to oxidative and nitrosative stress.(152) The same 
degree of oxidative stress may then induce variable effects 
on bioenergetic programs depending on the maintenance of 
mitochondrial quality and coordination between biogenesis 
and mitophagy.(153) The importance of autophagy in 
aging is supported by observations that yeast, C.elegans 
and flies with impaired autophagy have decreased lifespan. 
This contributes to the notion that that autophagy plays an 
important role in the aging.(154-156)
 Furthermore, pharmacologic or genetic manipulations 
that increase life span in model organisms often stimulate 
autophagy (138,157-163). For example, inhibition of 
mammalian target of rapamycin (mTOR) by rapamycin, 
which enhances autophagy, extends health span and lifespan 
in model organisms.(164) The mechanisms of the effect of 
rapamycin are pleiotropic, including inhibition of protein 
synthesis, alteration of transcriptomes, modulation of 
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inflammation, and improvement of cerebral blood flow, in 
addition to regulation of autophagy, mitophagy and thereby 
mitochondrial function.(157,161,165-177) Taken together, 
these examples provide strong support for the concept that 
autophagy plays a critical role in maintaining a normal 
lifespan and healthy neuronal aging, and that its decline is 
inexorably tied to age related pathologies (Figure 5).(178)
 Degradation of dysfunctional mitochondria is carried 
out by the autophagy-lysosomal pathway. Many lysosomal 
diseases result in deficient autophagic degradation of cellular 
materials. The alteration of mitochondrial morphology and 
decreased respiratory chain activity varies in both extent and 
characteristics in tissues and isolated mitochondria among 
these diseases.(179) The lysosomotropic agent chloroquine 
or the lysosomal protease cathepsin D inhibitor pepstatin A 
have both been shown to increase the formation of reactive 
species.(180-184) Improving lysosomal biogenesis, 
increasing specific hydrolases, or decreasing lysosomal 
protease inhibitors have all been explored as neuroprotective 
strategies.(185-187) Here we highlight some of the 
evidence that autophagy may serve as an antioxidant and 
anti-proteotoxicity pathway and provide a beneficial impact 
on neuronal bioenergetic health and survival.(178)
 Autophagy is important for redox homeostasis, 
mitochondrial quality control, cell proliferation and 
survival.(153,188,189) Furthermore, studies have 
found that autophagy and lysosomal gene expression 
may be coordinately regulated at transcriptional and 
post-transcriptional levels, and that genetic mutations 
Figure 5. Autophagy serves as an essential neuroprotective pathway in response to mitochondrial dysfunction and oxidative stress.
(178) (Adapted with permission from Redmann M).
of autophagy genes lead to abnormal cell and tissue 
homeostasis.(190-193) It is well recognized that 
mitochondrial dysfunction and increased oxidative stress 
play important roles in brain aging and the development of 
NDDs. Our recent findings that decreased mTOR signaling 
and dietary restriction are novel stimuli for mitochondrial 
localization of TERT protein, and the role of the telomerase 
protein TERT in brain on lowering mitochondrial ROS in 
an mTOR signaling dependent manner, therefore identify 
new players and connections in an ever bigger network 
of signaling events in the brain. Consequently, mTOR 
signalling and TERT protein could be potential therapeutic 
targets for neuropathological conditions via improvement 
of mitochondrial quality and decreased oxidative stress.
(194,195)
Proteostasis and Protein Seeding Defects in NDD
A typical mammalian cell contains more than 10,000 different 
proteins that are involved in virtually all its biological 
processes. Following their synthesis on ribosomes as linear 
chains of amino acids, proteins generally  must fold to 
unique three-dimensional structures to become functionally 
active.(196) Proteins are essential to cellular metabolism 
and communication, and they form the framework on which 
cells and tissues are built. To undertake these roles, most 
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proteins fold into a specific, three-dimensional architecture 
that is largely determined by their distinctive sequences of 
amino acids. Others have a degree of structural flexibility 
that enables them to tailor their shape to the task at hand.
(197,198) Hence, it is critical for cells to maintain an 
efficient quality-control system that ensures the proper 
production, folding and elimination of proteins.(199,200) 
When a protein misfolds and evades normal clearance 
pathways, a pathogenic process can ensue in which the 
protein aggregates progressively into intracellular and/
or extracellular deposits. The consequence is a diverse 
group of disorders, each of which entails the aggregation of 
particular proteins in characteristic patterns and locations.
(20,21,33,201) New insights into the ontogeny of these 
proteopathies are beginning to emerge from the unusual 
properties of the prion, arguably one of the most provocative 
molecules in the annals of medicine.(202)
 Because the ability to form cytotoxic aggregates is 
a widespread feature amongst proteins, cells contain an 
extensive network of factors to safeguard the integrity 
of the proteome, collectively referred to as the protein 
homoeostasis proteostasis network (PN). Molecular 
chaperones of various classes have a central role within the 
PN by mediating the folding of newly synthesized proteins, 
the refolding of stress-denatured proteins and the transfer 
of irreversibly misfolded proteins to the protein degradation 
machineries. Chaperones perform these functions primarily 
by preventing the aggregation of misfolded and incompletely 
folded protein molecules in the densely crowded cellular 
milieu, and therefore provide protection against cytotoxic 
protein species. The capacity of the chaperone system to 
Figure 6. Off-pathway reactions of protein folding leading to 
aggregation.(196) (Adapted with permission from The Association 
for the Publication of the Journal of Internal Medicine).
prevent or reverse toxic aggregates declines during aging, 
facilitating the manifestation of a range of NDDs and other 
pathologies (Figures 6).(196)
 Amyloid diseases, or the amyloidoses, are characterized 
by the deposition of cross-b-sheet amyloid fibrils consisting 
of misfolded and/or misassembled proteins.(203-205) The 
amyloid fibrils that are the pathological hallmark of these 
disorders can be either deposited systemically or localized 
to specific organs. The development of amyloidosis is 
often linked to aging and is associated with a decreased 
quality of life and substantial suffering for both patients 
and their families. AD is an example of a localized cerebral 
amyloidosis and type 2 diabetes mellitus is an example 
of localized extracerebral amyloidosis; both diseases are 
associated with aging.(206)
 Transthyretin (TTR) (207), immunoglobulin light 
chain (LC) (208), serum amyloid A (SAA) (209), and 
Aβ (210)  are  examples  of  more  than  thirty human 
proteins whose misfolding and/or misassembly into a 
variety of aggregate structures appear to cause a spectrum 
of degenerative disorders (211). These so-called amyloid 
diseases are named after the cross-β-sheet aggregates, or 
amyloid   fibrils,   that  are  the  pathological hallmarks 
of these maladies.(212,213) Amyloid fibrils in a specific 
disease are generally composed predominantly of one 
protein5. Amyloid fibrils from different diseases and 
composed of different proteins exhibit similar structural 
features.(212) 
 The origin of amyloidosis is either sporadic, i.e., from 
the normal protein sequence, or hereditary (familial), i.e., 
from a protein harbouring one or more point mutations.
(214) In addition, there re infectious forms of amyloidosis, 
such as the transmissible spongiform encephalopathies 
caused by the aggregation of prion protein.(214,216) The 
aggregation of specific proteins is hypothesized to underlie 
several degenerative diseases, collectively called amyloid 
disorders.(217) Progressive accumulation of aggregates of 
specific proteins in the brain is a defining feature of many 
common NDDs, including AD, PD and frontotemporal 
dementia (FTD).(204,218) Certain rare infectious 
neurological diseases known as transmissible spongiform 
encephalopathies (TSEs) are associated with abnormal 
folding and aggregation of PrP (219), and the steady 
accumulation of PrP aggregates is a necessary prequel to 
neurodegeneration in most TSEs. It has been speculated that 
the protein deposits present in other NDDs may form and 
spread from region to region in a manner analogous to that 
of misfolded PrP in TSEs.(220,221) A recent comprehensive 
review from scientist who support this hypothesis concluded 
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that “the paradigm of pathological protein propagation in 
NDD is now firmly established”.(222)
 Prions (‘proteinaceous infectious particles’) are 
unconventional infectious agents consisting of misfolded 
PrP molecules. In their misshapen state, the molecules 
aggregate with one another and impose their anomalous 
structure on benign PrP molecules.(223-226) Prions thus 
act as corruptive templates that incite a chain-reaction of 
PrP misfolding and aggregation. As prions grow, fragment 
and spread, they perturb the function of the nervous system 
and ultimately cause the death of the affected individual. 
The essence of prion disease is a crystallization-like chain 
reaction by which malformed PrP seeds force naive PrP 
molecules into a similar pathogenic architecture. Recent 
findings now suggest that this ‘prion paradigm’ also underlies 
the ontogeny of a widening spectrum of maladies, including 
common age-related NDDs such as AD and PD. In many of 
these disorders, as in prion disease, the aggregating proteins 
form characteristic lesions generically known as amyloid.
(202,227)
 The pathogenic spread hypothesis suggests that the 
progressive accumulation of protein aggregates across 
Figure 7. The pathogenic spread and selective vulnerability hypotheses.(232) (Adapted with permission from Springer Ltd).
neuronal populations and brain regions that is observed 
in common NDDs (21,23,232) is analogous to the 
accumulation of PrP3 within the brain in TSEs, in terms 
of both its mechanisms and its contribution to symptom 
progression (Figure 7). Proponents of this hypothesis 
therefore characterize the spreading mechanism in diseases 
such as AD, PD or FTD as ‘prion disease’ (220), prion-like 
(221,228,229) or ‘prionoid’ (230,231).
 Principal alternative hypothesis for the progressive 
involvement of regional populations of neurons in protein 
misfolding diseases is the concept of selective neuronal 
vulnerability. According to this older concept, certain 
neurons are intrinsically more vulnerable to the underlying 
pathogenic processes of a disease (such as those that cause 
the misfolding and aggregation of a certain protein) than 
others (233,234), perhaps because of their gene expression 
profiles, and that these vulnerable neurons thus become 
dysfunctional and structurally abnormal earlier than the 
others. The pathogenic spread hypothesis tends to emphasize 
a non-cell-autonomous mechanism of disease, whereas 
the selective neuronal vulnerability hypothesis tends to 
emphasize a more cell-autonomous mechanism.(232)
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